- Ligand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
- Ligand Provides Highlights from its Investor and Analyst Day Event
- Ligand Pharmaceuticals Names Director Todd C. Davis as CEO
- Ligand to Hold Investor and Analyst Day on December 13
- OmniAb Reports Third Quarter 2022 Financial Results and Business Highlights
More ▼
Key statistics
As of last trade Ligand Pharmaceuticals Inc (LGND:NMQ) traded at 71.92, -14.33% below its 52-week high of 83.95, set on Nov 14, 2022.
52-week range
Markit short selling activity
Open | 71.14 |
---|---|
High | 72.99 |
Low | 71.14 |
Bid | 71.74 |
Offer | 72.08 |
Previous close | 71.45 |
Average volume | 108.26k |
---|---|
Shares outstanding | 16.89m |
Free float | 15.95m |
P/E (TTM) | -- |
Market cap | 1.21bn USD |
EPS (TTM) | -1.27 USD |
Data delayed at least 15 minutes, as of Feb 06 2023 20:06 GMT.
More ▼